Entrada Therapeutics Announces Recipients of Third Annual DREAMS Grant Program

Core Points - Entrada Therapeutics announced the recipients of its third annual DREAMS Grant Program, awarding $50,000 each to Jett Foundation (U.S.) and Parent Project aps (Italy) to support the Duchenne muscular dystrophy community [1][2] - The grants aim to fund projects that enhance equity, accessibility, and inclusion for underrepresented or underserved individuals living with Duchenne [1][2] Group 1: Grant Program Details - The DREAMS Grant Program is designed to support organizations working to identify and reach members of the Duchenne community globally [1][2] - The 2025 grants were announced ahead of World Duchenne Awareness Day on September 7 [1] - Jett Foundation will use the funds to support its Camp Promise program, which focuses on independent living and self-advocacy for individuals aged 18 and older [5] - Parent Project aps will utilize the grant to provide home-based care and teleconsultation services in underserved regions of Southern Italy [5] Group 2: Organizational Commitment - Entrada Therapeutics emphasizes its commitment to the Duchenne community beyond therapeutic development, engaging with patients and families to understand their needs [2] - The expansion of the grant program to include organizations from the U.S., EU, and U.K. reflects this commitment [2] - The independent grant review committee, composed of neuromuscular leaders and advocates, played a crucial role in selecting the grant recipients [4] Group 3: Organizational Background - Jett Foundation is based in Massachusetts and focuses on enriching the lives of individuals affected by Duchenne through family support services and educational initiatives [5] - Parent Project aps, founded by parents, aims to promote scientific research and improve access to care for individuals with Duchenne and Becker muscular dystrophy [5] - Entrada Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines targeting intracellular delivery for neuromuscular diseases [6]